Novo Nordisk's Semaglutide 2.4 mg Achieves Primary Endpoints In Essence Trial, Showing Significant Improvement In Liver Fibrosis And MASH Resolution At Week 72 With Positive Safety Profile; Regulatory Filings Planned For U.S. And EU In 1H 2025, With Detailed Results To Be Presented This Year And Part 2 Readout Expected In 2029
Portfolio Pulse from Benzinga Newsdesk
Novo Nordisk's Semaglutide 2.4 mg has achieved primary endpoints in the Essence trial, showing significant improvement in liver fibrosis and MASH resolution at week 72 with a positive safety profile. Regulatory filings are planned for the U.S. and EU in the first half of 2025.
November 01, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novo Nordisk's Semaglutide 2.4 mg has shown significant improvement in liver fibrosis and MASH resolution in the Essence trial, with regulatory filings planned for 2025.
The successful achievement of primary endpoints in the Essence trial for Semaglutide 2.4 mg indicates a positive development for Novo Nordisk. The planned regulatory filings in major markets like the U.S. and EU suggest potential future revenue growth, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100